Bloomberg Television
@markets·3.2M subscribers·95.6K videos
J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine
Posted
May 2, 2026
Views
38,352
Likes
832
Comments
98
Engagement
May 2, 2026
38,352
832
98
2.42%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
4:46Now PlayingSpravato, the ketamine-derived nasal spray from Johnson & Johnson, was once seen as a long shot. It was difficult to deliver, heavily regulated and slow to catch on. Find out how it became a billion-dollar drug and part of a new model for treating depression.
Watch more mini documentaries from Bloomberg
The $1.7 Billion Trip
How J&J leveraged insurance to turn Spravato into a blockbuster depression drug.
Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance
Visit for business news & analysis, uptotheminute market data, features, profiles and more.
#Ketamine #Science #Business
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
